<bill session="110" type="s" number="2351" updated="2013-07-19T22:41:22-04:00">
  <state datetime="2007-11-14">REFERRED</state>
  <status>
    <introduced datetime="2007-11-14"/>
  </status>
  <introduced datetime="2007-11-14"/>
  <titles>
    <title as="introduced" type="official">A bill to amend the Internal Revenue Code of 1986 to provide a tax credit for medical research related to developing qualified infectious disease products.</title>
  </titles>
  <sponsor id="300087"/>
  <cosponsors>
    <cosponsor id="300052" joined="2007-12-03"/>
  </cosponsors>
  <actions>
    <action state="REFERRED" datetime="2007-11-14">
      <text>Read twice and referred to the Committee on Finance.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSFI" name="Senate Finance" activity="Referral, In Committee"/>
  </committees>
  <relatedbills>
    <bill relation="identical" session="110" type="h" number="4200"/>
  </relatedbills>
  <subjects>
    <term name="Taxation"/>
    <term name="Antibiotics"/>
    <term name="Commerce"/>
    <term name="Communicable diseases"/>
    <term name="Drug industry"/>
    <term name="Health"/>
    <term name="Income tax"/>
    <term name="Medical tests"/>
    <term name="Pharmaceutical research"/>
    <term name="Preventive medicine"/>
    <term name="Research and development tax credit"/>
    <term name="Science, technology, communications"/>
    <term name="Vaccines"/>
    <term name="Virus diseases"/>
  </subjects>
  <amendments/>
  <summary>11/14/2007--Introduced.
Amends the Internal Revenue Code to allow a general business tax credit for 50% of expenses paid for research and development of any qualified infectious disease product. Defines "qualified infectious disease product" as any antibiotic drug, antiviral, diagnostic test, biological product, or vaccine developed to treat, detect, prevent, or identify certain pathogens. Terminates such credit after 2012.</summary>
</bill>
